SwissPedDose, Zurich, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland.
Eur J Pediatr. 2022 Mar;181(3):1221-1231. doi: 10.1007/s00431-021-04304-8. Epub 2021 Nov 5.
In daily paediatrics, drugs are commonly used off-label, as they are not approved for children. Approval is lacking because the required clinical studies were limited to adults in the past. Without clinical studies, evidence-based recommendations for drug use in children are limited. Information on off-label drug dosing in children can be found in different handbooks, databases and scientific publications but the dosing recommendations can differ considerably. To improve safety and efficacy of drugs prescribed to children and to assist the prescribers, stakeholders in Swiss paediatrics started a pilot project, supported by the Federal Office of Public Health, with the aim to create a database, providing healthcare professionals with so called "harmonised" dosage recommendations based on the latest available scientific evidence and best clinical practice. A standardised process for dosage harmonisation between paediatric experts was defined, guided and documented in an electronic tool, developed for this purpose. As proof of principle, a total of 102 dosage recommendations for 30 different drugs have been nationally harmonised in the pilot phase considering the current scientific literature and the approval of the most experienced national experts in the field.Conclusion: This approach paved the way for unified national dosage recommendations for children. Reaching the project's milestones fulfilled the prerequisites for funding and starting regular operation of SwissPedDose in 2018. Since then, the database was extended with recommendations for 100 additional drugs. What is Known: • Prescribing off-label is a common practice among paediatricians, as many drugs are still not authorised for use in children. • Some countries developed national drug formularies providing off-label dosage recommendations. What is New: • Comparison of published dosage recommendations in known drug handbooks and online databases show substantial differences and heterogeneity, revealing the need for harmonisation. • The design of a tool for standardised harmonisation of dosage recommendations, based on information collected on currently applied dosages, latest scientific evidence and the approval of experts.
在日常儿科中,药物经常被超说明书使用,因为它们尚未获得儿童用药批准。过去,由于缺乏所需的临床研究,药物无法获得批准。在缺乏临床研究的情况下,基于证据的儿童用药推荐也受到限制。关于儿童超说明书用药剂量的信息可以在不同的手册、数据库和科学出版物中找到,但剂量建议可能存在较大差异。为了提高儿童用药的安全性和疗效,并为处方医生提供帮助,瑞士儿科学会的利益相关者在联邦公共卫生办公室的支持下启动了一个试点项目,旨在创建一个数据库,为医疗保健专业人员提供所谓的“统一”剂量建议,这些建议基于最新的可用科学证据和最佳临床实践。在一个为此目的开发的电子工具的指导和记录下,为儿科专家之间的剂量统一制定了一个标准化流程。作为原理验证,在试点阶段,考虑到当前的科学文献和该领域最有经验的国家专家的批准,全国范围内对 30 种不同药物的总共 102 种剂量建议进行了统一协调。结论:这种方法为儿童的全国统一剂量建议铺平了道路。达到项目的里程碑为 2018 年瑞士儿科剂量数据库的资金申请和定期运行奠定了基础。自那时以来,数据库又增加了 100 种药物的建议。已知情况:• 开处方超说明书使用是儿科医生的常见做法,因为许多药物仍未获准用于儿童。• 一些国家制定了国家药物处方集,提供超说明书剂量建议。新内容:• 比较已知药物手册和在线数据库中公布的剂量建议,显示出显著差异和异质性,这表明需要进行协调。• 基于当前应用剂量、最新科学证据和专家认可的信息,设计了一种用于标准化剂量建议协调的工具。